Long-chain acylcarnitines reduce lung function by inhibiting pulmonary surfactant

Journal of Biological Chemistry

Volumn 290, Issue 39, 2015, Pages 23897-23904

  Otsubo, Chikara ^a   Bharathi, Sivakama ^a   Uppala, Radha ^a   Ilkayeva, Olga R ^b   Wang, Dongning ^b   McHugh, Kevin ^a   Zou, Ye ^c   Wang, Jieru ^a   Alcorn, John F ^a   Zuo, Yi Y ^c   Hirschey, Matthew D ^b   Goetzman, Eric S ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University of Hawaii at Manoa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIR; BIOLOGICAL ORGANS; DIETARY SUPPLEMENTS; FATTY ACIDS; HEALTH RISKS; MAMMALS; METABOLISM; MITOCHONDRIA; PHOSPHOLIPIDS; PHYSIOLOGY; SURFACE ACTIVE AGENTS; SURFACE TENSION;

ACYLCARNITINES; DIETARY SUPPLEMENTATION; FATTY ACID OXIDATION; FLUID INTERFACE; LONG-CHAIN ACYL-COA; MITOCHONDRIAL ENERGY; PULMONARY SURFACTANTS; SURFACE ADSORPTION;

CHAINS;

ACYLCARNITINE; CARNITINE; LUNG SURFACTANT; MELDONIUM; PHOSPHOLIPID; LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATELECTASIS; BIOACCUMULATION; BREATHING; CONTROLLED STUDY; DIET SUPPLEMENTATION; IN VITRO STUDY; INFLUENZA; LIPOGENESIS; LUNG ALVEOLUS SURFACE TENSION; LUNG FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG; LUNG INJURY; METABOLISM; PATHOLOGY;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ANIMALS; CARNITINE; HUMANS; LUNG; LUNG INJURY; MICE; MICE, KNOCKOUT; PHOSPHOLIPIDS; PULMONARY SURFACTANTS;

EID: 84942333070     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.655837     Document Type: Article

References (43)

1. Goetzman, E. S., and Alcorn, J. F., Bharathi, S. S., Uppala, R., McHugh, K. J., Kosmider, B., Chen, R., Zuo, Y. Y., and Beck, M. E., McKinney, R. W., Skilling, H., Suhrie, K. R., Karunanidhi, A., Yeasted, R., Otsubo, C., Ellis, B., and Tyurina, Y. Y., Kagan, V. E., Mallampalli, R. K., and Vockley, J. (2014) Long-chain Acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. J. Biol. Chem. 289, 10668-10679
2. Guillot, L., Nathan, N., Tabary, O., Thouvenin, G., Le Rouzic, P., Corvol, H., Amselem, S., and Clement, A. (2013) Alveolar epithelial cells: master regulators of lung homeostasis. Int. J. Biochem. Cell Biol. 45, 2568-2573
3. Miller, M. L., Andringa, A., and Hastings, L. (1995) Relationships between the nuclear membrane, nuclear pore complexes, and organellesin the type II pneumocyte. Tissue Cell 27, 613-619
4. Millington, D. S., and Stevens, R. D. (2011) Acylcarnitines: analysis in plasma and whole blood using tandem mass spectrometry. Methods Mol. Biol. 708, 55-72
5. Jones, L. L., and McDonald, D. A., and Borum, P. R. (2010) Acylcarnitines: role in brain. Progr. Lipid Res. 49, 61-75
6. Kurth, L., Fraker, P., and Bieber, L. (1994) Utilization of intracellular acylcarnitine pools by mononuclear phagocytes. Biochim. Biophys. Acta 1201, 321-327
7. Onofrj, M., Ciccocioppo, F., Varanese, S., di Muzio, A., Calvani, M., Chiechio, S., Osio, M., and Thomas, A. (2013) Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Exp. Rev. Neurotherap. 13, 925-936
8. Reuter, S. E., and Evans, A. M. (2012) Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clinical Pharmacokinetics 51, 553-572
9. Schooneman, M. G., and Vaz, F. M., Houten, S. M., and Soeters, M. R. (2013) Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62, 1-8
10. Doi, N., Tomita, M., and Hayashi, M. (2011) Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers. Drug Metab. Pharmacokinetics 26, 162-170
11. Adams, S. H., and Hoppel, C. L., Lok, K. H., Zhao, L., Wong, S. W., and Minkler, P. E., Hwang, D. H., Newman, J. W., and Garvey, W. T. (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 139, 1073-1081
12. DaTorre, S. D., and Creer, M. H., Pogwizd, S. M., and Corr, P. B. (1991) Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J. Mol. Cell Cardiol. 23, 11-22
13. Braciale, T. J. (1977) Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell. Immunol. 33, 423-436
14. Wang, J., and Nikrad, M. P., Phang, T., Gao, B., Alford, T., Ito, Y., Edeen, K., Travanty, E. A., Kosmider, B., Hartshorn, K., and Mason, R. J. (2011) Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 45, 582-591
15. Kao, H. J., and Cheng, C. F., Chen, Y. H., Hung, S. I., and Huang, C. C., Millington, D., Kikuchi, T., Wu, J. Y., and Chen, Y. T. (2006) ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit. Hum. Mol. Genet. 15, 3569-3577
16. An, J., and Muoio, D. M., Shiota, M., Fujimoto, Y., Cline, G. W., and Shulman, G. I., Koves, T. R., Stevens, R., Millington, D., and Newgard, C. B. (2004) Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10, 268-274
17. Zuo, Y. Y., Ding, M., Li, D., and Neumann, A. W. (2004) Further development of Axisymmetric Drop Shape Analysis-captive bubble for pulmonary surfactant related studies. Biochim. Biophys. Acta 1675, 12-20
18. Valle, R. P., Liwen-Huang, C., Loo, J. S., and Zuo, Y. Y. (2014) Increasing Hydrophobicity of Nanoparticles Intensifies Lung Surfactant Film Inhibition and Particle Retention. ACS Sustainable Chemistry and Engineering 2, 6
19. Liepinsh, E., Konrade, I., Skapare, E., Pugovics, O., Grinberga, S., Kuka, J., Kalvinsh, I., and Dambrova, M. (2011) Mildronate treatment alters gamma-butyrobetaine and l-carnitine concentrations in healthy volunteers. J. Pharmacy Pharmacol. 63, 1195-1201
20. Icard, P., and Saumon, G. (1999) Alveolar sodium and liquid transport in mice. Am. J. Physiol. 277, L1232-1238
21. Bakermans, A. J., van Weeghel, M., Denis, S., Nicolay, K., and Prompers, J. J., and Houten, S. M. (2013) Carnitine supplementation attenuates myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice. J. Inherit. Metab. Dis. 36, 973-981
22. Nasser, M., Javaheri, H., Fedorowicz, Z., and Noorani, Z. (2012) Carnitine supplementation for inborn errors of metabolism. Cochrane Database System Review 2, 1-24
23. Veiga, M. P., and Requero, M. A., Goñi, F. M., and Alonso, A. (1996) Effect of long-chain acyl-CoAs and acylcarnitines on gel-fluid and lamellar-hexagonal phospholipid phase transitions. Molecular Membrane Biology 13, 165-172
24. Lopez-Rodriguez, E., and Perez-Gil, J. (2014) Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy. Biochim. Biophys. Acta
25. Sjakste, N., Gutcaits, A., and Kalvinsh, I. (2005) Mildronate: an antiischemic drug for neurological indications. CNS Drug Reviews 11, 151-168
26. Duan, Y., Learoyd, J., Meliton, A. Y., and Leff, A. R., and Zhu, X. (2012) Inhibition of Pyk2 blocks lung inflammation and injury in a mouse model of acute lung injury. Respir. Res. 13, 4
27. Madala, S. K., and Maxfield, M. D., Davidson, C. R., Schmidt, S. M., Garry, D., Ikegami, M., Hardie, W. D., and Glasser, S. W. (2011) Rapamycin Regulates Bleomycin-Induced Lung Damage in SP-C-Deficient Mice. Pulmonary Medicine 2011, 653524
28. Lundy, C. T., and Shield, J. P., Kvittingen, E. A., Vinorum, O. J., and Trimble, E. R., and Morris, A. A. (2003) Acute respiratory distress syndrome in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies. Journal of inherited metabolic disease 26, 537-541
29. Gentili, A., Iannella, E., Masciopinto, F., Latrofa, M. E., Giuntoli, L., and Baroncini, S. (2008) Rhabdomyolysis and respiratory failure: rare presentation of carnitine palmityl-transferase II deficiency. Minerva Anestesiologica 74, 205-208
30. Spiekerkoetter, U., Bennett, M.J., Ben-Zeev, B., Strauss, A. W., and Tein, I. (2004) Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 29, 66-72
31. Tyni, T., Palotie, A., Viinikka, L., Valanne, L., and Salo, M. K., von Döbeln, U., Jackson, S., Wanders, R., Venizelos, N., and Pihko, H. (1997) Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation of thirteen patients. J. Pediatr. 130, 67-76
32. Sampey, B. P., and Freemerman, A. J., Zhang, J., Kuan, P. F., and Galanko, J. A., O'Connell, T. M., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D., Newgard, C. B., Brauer, H. A., Troester, M. A., and Makowski, L. (2012) Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. PLoS ONE 7, e38812
33. Mihalik, S. J., and Goodpaster, B. H., Kelley, D. E., Chace, D. H., Vockley, J., and Toledo, F. G., and DeLany, J. P. (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity 18, 1695-1700
34. Kalim, S., and Clish, C. B., Wenger, J., Elmariah, S., Yeh, R. W., and Deferio, J. J., Pierce, K., Deik, A., Gerszten, R. E., Thadhani, R., and Rhee, E. P. (2013) A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J. Am. Heart Assoc. 2, e000542
35. Ussher, J. R., Keung, W., Fillmore, N., Koves, T. R., Mori, J., Zhang, L., Lopaschuk, D. G., and Ilkayeva, O. R., Wagg, C. S., Jaswal, J. S., and Muoio, D. M., and Lopaschuk, G. D. (2014) Treatment with the 3-Ketoacyl-CoA Thiolase Inhibitor Trimetazidine Does Not Exacerbate Whole-Body Insulin Resistance in Obese Mice. J. Pharmacol. Exp. Ther. 349, 487-496
36. Lionetti, V., Stanley, W.C., and Recchia, F. A. (2011) Modulating fatty acid oxidation in heart failure. Cardiovasc. Res. 90, 202-209
37. Grunnet, N., and Kondrup, J. (1986) The effect of ethanol on the beta-oxidation of fatty acids. Alcohol. Clin. Exp. Res. 10, 64S-68S
38. Requero, M. A., Goñi, F. M., and Alonso, A. (1995) The membrane-perturbing properties of palmitoyl-coenzyme A and palmitoylcarnitine. A comparative study. Biochemistry 34, 10400-10405
39. Duizer, E., van der Wulp, C., Versantvoort, C. H., and Groten, J. P. (1998) Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells. J. Pharmacol. Exp. Ther. 287, 395-402
40. Goñi, F. M., Requero, M. A., and Alonso, A. (1996) Palmitoylcarnitine, a surface-active metabolite. FEBS Lett. 390, 1-5
41. Hayashi, M., Sakai, T., Hasegawa, Y., Nishikawahara, T., Tomioka, H., Iida, A., Shimizu, N., Tomita, M., and Awazu, S. (1999) Physiological mechanism for enhancement of paracellular drug transport. Journal of Controlled Release 62, 141-148
42. Zhu, Y., Zhang, G., Zhao, J., Li, D., Yan, X., Liu, J., Liu, X., Zhao, H., Xia, J., Zhang, X., Li, Z., Zhang, B., Guo, Z., Feng, L., Zhang, Z., Qu, F., and Zhao, G. (2013) Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. Clin. Drug Investig. 33, 755-760
43. Dzerve, V., and MILSS I Study Group (2011) A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial "MILSS I". Medicina 47, 544-551